Citations (36)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Fabrice Barlesi, Adrien Dixmier, Didier Debieuvre, Christophe Raspaud, Jean-Bernard Auliac, Nicolas Benoit, Pierre Bombaron, Denis Moro-Sibilot, Clarisse Audigier-Valette, Bernard Asselain, Thomas Egenod, Audrey Rabeau, Jérôme Fayette, Myriam Locatelli Sanchez, Jean-Luc Labourey, Virginie Westeel, Pauline Lamoureux, François-Emery Cotte, Victoria Allan, Melinda Daumont, Juliette Dumanoir, Dorothée Reynaud, Christophe Yannick Calvet, Nicolas Ozan & Maurice Pérol. (2020) Effectiveness and safety of nivolumab in the treatment of lung cancer patients in France: preliminary results from the real-world EVIDENS study. OncoImmunology 9:1.
Read now
Read now
Birgitte Bjørnhart, Karin H. Hansen, Trine L. Jørgensen, Jørn Herrstedt & Tine Schytte. (2019) Efficacy and safety of immune checkpoint inhibitors in a Danish real life non-small cell lung cancer population: a retrospective cohort study. Acta Oncologica 58:7, pages 953-961.
Read now
Read now
Ann Rita Halvorsen, Vandana Sandhu, Mette Sprauten, Vidar G. Flote, Elin H. Kure, Odd Terje Brustugun & Åslaug Helland. (2018) Circulating microRNAs associated with prolonged overall survival in lung cancer patients treated with nivolumab. Acta Oncologica 57:9, pages 1225-1231.
Read now
Read now
Articles from other publishers (33)
Yoshihiko Tasaki, Yosuke Sugiyama, Shuzo Hamamoto, Taku Naiki, Takehiro Uemura, Keisuke Yokota, Daisuke Kawakita, Motoki Nakamura, Ryo Ogawa, Takaya Shimura, Yoshihisa Mimura, Yuji Hotta, Kunihiro Odagiri, Nanami Ito, Moeko Iida, Yuka Kimura, Hirokazu Komatsu, Hiromi Kataoka, Shuji Takiguchi, Akimichi Morita, Shinichi Iwasaki, Katsuhiro Okuda, Akio Niimi, Takahiro Yasui & Yoko Furukawa‐Hibi. (2023) Eosinophil may be a predictor of immune‐related adverse events induced by different immune checkpoint inhibitor types: A retrospective multidisciplinary study. Cancer Medicine.
Crossref
Crossref
Laura Bonanno, Martina Lorenzi, Davide Massa, Mattia De Nuzzo, Valentina Angerilli, Fabiana Zingone, Brigida Barberio, Alberto Russi, Fabio Girardi, Alessandra Ferro, Alessandro Dal Maso, Stefano Frega, Giulia Pasello, Angelo Paolo Dei Tos, Marina Coppola, Matteo Fassan, Edoardo Vincenzo Savarino & Valentina Guarneri. (2023) Immune-Related Diarrhea and Colitis in Non-small Cell Lung Cancers: Impact of Multidisciplinary Management in a Real-World Setting. The Oncologist.
Crossref
Crossref
Ting Yan, Lun Yu, Dangang Shangguan, Wei Li, Ni Liu, Yun Chen, Yilan Fu, Jingyi Tang & Dehua Liao. (2023) Advances in pharmacokinetics and pharmacodynamics of PD-1/PD-L1 inhibitors. International Immunopharmacology 115, pages 109638.
Crossref
Crossref
Shivani Setur Kanabar, Abhinav Tiwari, Vina Soran, Prashanthan Balendran, Malcolm Price & Alice Margaret Turner. (2022) Impact of PD1 and PDL1 immunotherapy on non-small cell lung cancer outcomes: a systematic review. Thorax 77:12, pages 1163-1174.
Crossref
Crossref
Giulia Pasello, Martina Lorenzi, Lorenzo Calvetti, Cristina Oliani, Alberto Pavan, Adolfo Favaretto, Giovanni Palazzolo, Petros Giovanis, Fable Zustovich, Andrea Bonetti, Daniele Bernardi, Marta Mandarà, Giuseppe Aprile, Giovanna Crivellaro, Giusy Sinigaglia, Sandro Tognazzo, Paolo Morandi, Alberto Bortolami, Valentina Marino, Laura Bonanno, Valentina Guarneri & PierFranco Conte. (2022) Multicenter Real-World Study on Effectiveness and Early Discontinuation Predictors in Patients With Non-small Cell Lung Cancer Receiving Nivolumab. The Oncologist 27:6, pages e484-e493.
Crossref
Crossref
Chengming Liu, Sihui Wang, Sufei Zheng, Fei Xu, Zheng Cao, Xiaoli Feng, Yan Wang, Qi Xue, Nan Sun & Jie He. (2021) Avoiding Absolute Quantification Trap: A Novel Predictive Signature of Clinical Benefit to Anti-PD-1 Immunotherapy in Non-Small Cell Lung Cancer. Frontiers in Immunology 12.
Crossref
Crossref
Bartłomiej Tomasik, Michał Bieńkowski, Marcin Braun, Sanjay Popat & Rafał Dziadziuszko. (2021) Effectiveness and safety of immunotherapy in NSCLC patients with ECOG PS score ≥2 – Systematic review and meta-analysis. Lung Cancer 158, pages 97-106.
Crossref
Crossref
Manlio Mencoboni, Marcello Ceppi, Marco Bruzzone, Paola Taveggia, Alessia Cavo, Francesca Scordamaglia, Marina Gualco & Rosa Angela Filiberti. (2021) Effectiveness and Safety of Immune Checkpoint Inhibitors for Patients with Advanced Non Small-Cell Lung Cancer in Real-World: Review and Meta-Analysis. Cancers 13:6, pages 1388.
Crossref
Crossref
Wolfgang M. Brückl, Martin Reck, Frank Griesinger, Harald Schäfer, Cornelius Kortsik, Tobias Gaska, Justyna Rawluk, Stefan Krüger, Konrad Kokowski, Stephan Budweiser, Joachim H. Ficker, Christopher Hoffmann, Andrea Schüler & Eckart Laack. (2021)
Afatinib as first-line treatment in patients with
EGFR
-mutated non-small cell lung cancer in routine clinical practice
. Therapeutic Advances in Medical Oncology 13, pages 175883592110123.
Crossref
Crossref
Irena Tan & Kavitha Ramchandran. (2020) The role of palliative care in the management of patients with lung cancer. Lung Cancer Management 9:4.
Crossref
Crossref
Jennifer La, David Cheng, Mary T. Brophy, Nhan V. Do, Jerry S.H. Lee, David Tuck & Nathanael R. Fillmore. (2020) Real-World Outcomes for Patients Treated With Immune Checkpoint Inhibitors in the Veterans Affairs System. JCO Clinical Cancer Informatics:4, pages 918-928.
Crossref
Crossref
Yong-Jin Kim, Mark Oremus, Helen H Chen, Thomas McFarlane, Devanshi Shah & Susan Horton. (2020) Real-world effectiveness of nivolumab in patients with non-small-cell lung cancer: a systematic review and meta-analysis. Future Oncology 16:27, pages 2045-2058.
Crossref
Crossref
Magdalena Knetki-Wróblewska, Dariusz M. Kowalski & Maciej Krzakowski. (2020) Nivolumab for Previously Treated Patients with Non-Small-Cell Lung Cancer—Daily Practice versus Clinical Trials. Journal of Clinical Medicine 9:7, pages 2273.
Crossref
Crossref
Giulia Pasello, Alberto Pavan, Ilaria Attili, Alberto Bortolami, Laura Bonanno, Jessica Menis, PierFranco Conte & Valentina Guarneri. (2020) Real world data in the era of Immune Checkpoint Inhibitors (ICIs): Increasing evidence and future applications in lung cancer. Cancer Treatment Reviews 87, pages 102031.
Crossref
Crossref
Marie-Rose B.S. Crombag, John B.A.G. Haanen, Paul Baas, Jos H. Beijnen & Alwin D.R. Huitema. (2020) Treatment of older patients with immune checkpoint inhibitors in routine clinical care as compared to inclusion in pivotal registration trials. Journal of Geriatric Oncology 11:3, pages 529-532.
Crossref
Crossref
Matteo Giaj Levra, François-Emery Cotté, Romain Corre, Christophe Calvet, Anne-Françoise Gaudin, John R. Penrod, Valentine Grumberg, Baptiste Jouaneton, Ronan Jolivel, Jean-Baptiste Assié & Christos Chouaïd. (2020) Immunotherapy rechallenge after nivolumab treatment in advanced non-small cell lung cancer in the real-world setting: A national data base analysis. Lung Cancer 140, pages 99-106.
Crossref
Crossref
A. Figueiredo, M.A. Almeida, M.T. Almodovar, P. Alves, A. Araújo, D. Araújo, F. Barata, L. Barradas, A. Barroso, U. Brito, E. Camacho, D. Canário, T. Cardoso, A. Chaves, L. Costa, J. Cunha, J. Duarte, F. Estevinho, M. Felizardo, J.P. Fernandes, L. Ferreira, L. Ferreira, P. Fidalgo, C. Freitas, P. Garrido, N. Gil, D. Hasmucrai, E. Jesus, J.A. Lopes, J.E. de Macedo, A. Meleiro, R. Neveda, F. Nogueira, M. Pantorotto, B. Parente, A. Pego, M. Rocha, J. Roque, C. Santos, J. Saraiva, E. Silva, S. Silva, S. Simões, M. Soares, E. Teixeira, T. Timóteo & V. Hespanhol. (2020) Real-world data from the Portuguese Nivolumab Expanded Access Program (EAP) in previously treated Non Small Cell Lung Cancer (NSCLC). Pulmonology 26:1, pages 10-17.
Crossref
Crossref
Eugene Muchnik, Kah Poh Loh, Myla Strawderman, Allison Magnuson, Supriya G. Mohile, Vered Estrah & Ronald J. Maggiore. (2019) Immune Checkpoint Inhibitors in Real‐World Treatment of Older Adults with Non–Small Cell Lung Cancer. Journal of the American Geriatrics Society 67:5, pages 905-912.
Crossref
Crossref
Hang Li, Mian Jiang, Ming Cui, Guoxing Feng, Jiali Dong, Yuan Li, Huiwen Xiao & Saijun Fan. (2019) MiR-365 enhances the radiosensitivity of non-small cell lung cancer cells through targeting CDC25A. Biochemical and Biophysical Research Communications 512:2, pages 392-398.
Crossref
Crossref
Myrto Lee, Hoan Ly, Clemens C. Möller & Michael S. Ringel. (2019) Innovation in Regulatory Science Is Meeting Evolution of Clinical Evidence Generation. Clinical Pharmacology & Therapeutics 105:4, pages 886-898.
Crossref
Crossref
Peng Song, Jingcheng Zhang, Congcong Shang & Li Zhang. (2019) Real-world evidence and clinical observations of the treatment of advanced non-small cell lung cancer with PD-1/PD-L1 inhibitors. Scientific Reports 9:1.
Crossref
Crossref
Martin Faehling, Marcel Kopp, Birgit Schwenk, Sabine Fallscheer, Sebastian Kramberg & Robert Eckert. (2019) Immuno-Oncological Treatment and Tumor Mass in Non-Small Cell Lung Cancer: Case-Control Analysis of Overall Survival in Routine Clinical Practice. Oncology 97:4, pages 228-235.
Crossref
Crossref
Prianka Bhattacharya, Scott K. Dessain & Tracey L. Evans. (2018) Palliative Care in Lung Cancer: When to Start. Current Oncology Reports 20:11.
Crossref
Crossref
B. Mennecier. (2018) L’immunothérapie dans le cancer bronchique non à petites cellules métastatique : les données de vie réelle. Revue des Maladies Respiratoires Actualités 10:4, pages 481-486.
Crossref
Crossref
Wei‐Di Yu, Huanhuan Wang, Qi‐Feng He, Yong Xu & Xiao‐Chen Wang. (2018) Long noncoding RNAs in cancer‐immunity cycle. Journal of Cellular Physiology 233:9, pages 6518-6523.
Crossref
Crossref
Odd Terje Brustugun, Bjørn Henning Grønberg, Lars Fjellbirkeland, Nina Helbekkmo, Marianne Aanerud, Tom Kristian Grimsrud, Åslaug Helland, Bjørn Møller, Yngvar Nilssen, Trond Eirik Strand & Steinar Kristian Solberg. (2018) Substantial nation-wide improvement in lung cancer relative survival in Norway from 2000 to 2016. Lung Cancer 122, pages 138-145.
Crossref
Crossref
Binghao Zhao, Wenxiong Zhang, Dongliang Yu, Jianjun Xu & Yiping Wei. (2018) The benefit and risk of nivolumab in non‐small‐cell lung cancer: a single‐arm meta‐analysis of noncomparative clinical studies and randomized controlled trials. Cancer Medicine 7:5, pages 1642-1659.
Crossref
Crossref
Zhizhen Dong, Jianrong Chen, Xuli Yang, Wenjie Zheng, Li Wang, Miao Fang, Mengna Wu, Min Yao & Dengfu Yao. (2018)
Ang-2
promotes lung cancer metastasis by increasing epithelial-mesenchymal transition
. Oncotarget 9:16, pages 12705-12717.
Crossref
Crossref
Kurt G. Tournoy, Michiel Thomeer, Paul Germonpré, Sofie Derijcke, Rebecca De Pauw, Daniëlla Galdermans, Karl Govaert, Elke Govaerts, Rob Schildermans, Isabelle Declercq, Nele De Brucker, Karin Pat, Rika Van Herreweghe, Luc Van Zandweghe, Luc Vanmaele, Valerie Van Damme, Heidi Marien, Sofie De Craene, Isabelle Fabry, Patrick Alexander, Piet Vercauter & Ingel Demedts. (2018) Does nivolumab for progressed metastatic lung cancer fulfill its promises? An efficacy and safety analysis in 20 general hospitals. Lung Cancer 115, pages 49-55.
Crossref
Crossref
Felicity Stark, Risini Weeratna, Lise Deschatelets, Komal Gurnani, Renu Dudani, Michael McCluskie & Lakshmi Krishnan. (2017) An Archaeosome-Adjuvanted Vaccine and Checkpoint Inhibitor Therapy Combination Significantly Enhances Protection from Murine Melanoma. Vaccines 5:4, pages 38.
Crossref
Crossref
Tom M.A. Wilkinson. (2017) Immune checkpoints in chronic obstructive pulmonary disease. European Respiratory Review 26:144, pages 170045.
Crossref
Crossref
Yanyan Tang, Yi He, Lei Shi, Liting Yang, Jinpeng Wang, Yu Lian, Chunmei Fan, Ping Zhang, Can Guo, Shanshan Zhang, Zhaojian Gong, Xiayu Li, Fang Xiong, Xiaoling Li, Yong Li, Guiyuan Li, Wei Xiong & Zhaoyang Zeng. (2017) Co-expression of AFAP1-AS1 and PD-1 predicts poor prognosis in nasopharyngeal carcinoma. Oncotarget 8:24, pages 39001-39011.
Crossref
Crossref
. (2017) Nivolumab. Reactions Weekly 1649:1, pages 193-193.
Crossref
Crossref